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Available online 2 June 2016Whole body docosahexaenoic acid (DHA, 22:6n-3) synthesis fromα-linolenic acid (ALA, 18:3n-3) is considered to
be very low, however, the daily synthesis-secretion of DHAmay be sufﬁcient to supply the adult brain. The current
study aims to assess whether whole body DHA synthesis-secretion kinetics are different when comparing plasma
ALA versus eicosapentaenoic acid (EPA, 20:5n-3) as the precursor. Male Long Evans rats (n = 6) were fed a 2%
ALA in total fat diet for eight weeks, followed by surgery to implant a catheter into each of the jugular vein and ca-
rotid artery and 3 h of steady-state infusion with a known amount of 2H-ALA and 13C-eicosapentaenoic acid (EPA,
20:5n3). Blood samples were collected at thirty-minute intervals and plasma enrichment of 2H- and 13C EPA, n−3
docosapentaenoic acid (DPAn-3, 22:5n-3) and DHAwere determined for assessment of synthesis-secretion kinetic
parameters. Results indicate a 13-fold higher synthesis-secretion coefﬁcient for DHA fromEPA as compared to ALA.
However, after correcting for the 6.6 fold higher endogenous plasmaALA concentration, no signiﬁcant differences in
daily synthesis-secretion (nmol/day) of DHA (97.6± 28.2 and 172± 62), DPAn-3 (853± 279 and 1139± 484) or
EPA (1587 ± 592 and 1628 ± 366) were observed from plasma unesteriﬁed ALA and EPA sources, respectively.
These results suggest that typical diets which are signiﬁcantly higher in ALA compared to EPA yield similar daily
DHA synthesis-secretion despite a signiﬁcantly higher synthesis-secretion coefﬁcient from EPA.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Docosahexaenoic acid (DHA, 22:6n-3) is an omega-3 (n−3) PUFA
highly enriched in the brain [1] and the heart [2]. n−3 PUFA cannot
be synthesized by mammals de novo, and DHA must therefore be con-
sumed directly or synthesized from shorter chain n−3 PUFA consumed
in the diet. The most prominent source of n−3 PUFA in the diet comes
from α-linolenic acid (ALA, 18:3n-3) that is highly enriched in
ﬂaxseeds, representing N50% of the total fatty acids present [3]. Thema-
jority of ALA in our diet, however, is derived from cooking oil sources
such as vegetable oil in Canada and soybean oil in the United States [4,
5]. Alternatively, EPA, a product of ALA metabolism, is consumed in
our diet primarily from marine-based foods, particularly in fatty ﬁshic acid; DHA, docosahexaenoic
acid methyl ester; Fn, turnover
ection; Jn, synthesis-secretion
ain polyunsaturated fatty acid;
Smax, maximum ﬁrst derivative;
, total lipid extract; TPA,
l Sciences, Faculty of Medicine,
rald Building, Toronto, Ontario
therel).
. This is an open access article undersuch as trout, salmon, sardines and herring [6]. Both ALA and EPA are
metabolic precursors to DHA, another n−3 PUFA found primarily in
seafood. Although high in fatty ﬁsh, the relative consumption in North
America for EPA (50mg per day) [7] is very low relative to ALA (approx-
imately 1500 mg per day) [4,8–10]. Even so, only a small proportion of
consumed ALA enters the DHA synthesis pathway with the majority
being metabolized elsewhere in the body [11].
Oral administration of stable-isotope labeled ALA for determination
of DHA synthesis rates is a popularmethod that assesses the appearance
of labeled DHA in blood lipids over time, and these methods have been
reviewed recently [12]. The appearance of DHA in blood from an oral
ALA dose ranges from non-detectable to 9.8%, with themajority of stud-
ies estimating conversion at less than 1% [13–22]. Fractional DHA syn-
thesis from ALA using this method ranges from 0.01 to 0.08% of orally
ingested stable-isotope ALA [18,21–23], nevertheless, recent evidence
suggests that although the daily conversion rates are low, it remains at
least 3-fold higher than brain uptake requirements in rats [24]. Al-
thoughmuch of the orally ingested tracers are either oxidized or stored
in adipose tissue [20], compartmental modelling is an extremely useful
tool for comparing multiple experimental groups or multiple tracers
within the same study. One previous study has compared co-ingestion
of stable-isotope labeled ALA and EPA using compartmental modelling
to determine fractional conversion rates in infants [25], demonstrating
3.5 fold and 1.6 fold higher fractional conversion rates to DHA for EPAthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Composition of 2% α-linolenic acid diet.
Fatty acid Weight %
C 10:0 1.03 ± 0.19
C 12:0 27.9 ± 0.8
C 14:0 13.9 ± 0.11
C 16:0 10.0 ± 0.1
C 18:0 9.29 ± 0.14
C 18:1n-9 8.97 ± 0.17
C 18:2n-6 25.6 ± 0.4
C 18:3n-3 1.95 ± 0.09
Values expressed as % weight of fatty acid in total fatty
acids (mean ± S.D.), n = 3.
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though these ﬁnding were from infants only, with fewer metabolic
steps DHA synthesis rates from EPA compared to ALA is likely higher
across the life cycle.
A steady-state infusion model developed by Rapoport et al. [26] and
modiﬁed by our lab [24] includes infusing labeled ALA to steady-state
and measures the appearance of labeled esteriﬁed DHA in the plasma.
This method minimizes effects of adipose storage and tissue uptake
thereby allowing for the determination of a whole body DHA
synthesis-secretion rate from plasma ALA directly. In the present
study, we are the ﬁrst to utilize this steady state infusion protocol for
the determination of DHA, DPAn-3 and EPA synthesis-secretion rates
following the co-infusion of 2H5-ALA and uniformly labeled (U)-13C-
EPA. From this we measured the rate of appearance of esteriﬁed 2H5-
DHA and 13C-DHA to determine the daily rates of n−3 PUFA
synthesis-secretion from the two fatty acid precursors.
2. Materials and methods
2.1. Animals
All experimental procedures were performed in agreement with the
policies set out by the Canadian Council on Animal Care and were
approved by the Animal Ethics Committee at the University of Toronto.
One Long Evans dam with six 18-day-old male non-littermate Long
Evans rats were ordered from Charles River Laboratories (St. Constant,
QC, Canada). Following arrival at the University of Toronto, the dam
and pups were acclimated for 3 days and then weaned at 21 days old.
The dam was placed on a DHA-free, 2% ALA diet immediately upon
arriving at the University of Toronto and the pups were placed on
the same diet for 8 weeks following weaning. During this time
and prior to cannulation, rats were handled frequently and housed in
pairs [24].
2.2. Diets
The diet was modiﬁed from the AIN-93G custom low n−3 rodent
diet (Dyets, Inc., Bethlehem, PA) [27]. The diet contained 10% lipids by
weight, and the fat content of the diet by weight was 32.8% safﬂower
oil, 63.2% hydrogenated coconut oil and 4% added oils. The added oils
were 2% oleate ethyl ester (Nu-Chek Prep, Inc., Elysian, MN) and 2%
ALA ethyl ester as the only n−3 fatty acid present in the diet as con-
ﬁrmed by GC-FID (Table 1) (gift from BASF Pharma Callanish Ltd., Isle
of Lewis, UK). Each oil was determined to be N98% pure by gas
chromatography-ﬂame ionization detection (GC-FID). The custom 2%
ALA AIN-93G diet is designed to be sufﬁcient in ALA and free of other
n−3 PUFA present, therebymodelling expected n−3 intakes. Other re-
search studies from our lab include 2% DHA in the diet, therefore, oleate
ethyl esterwas added to the diet to keep total fat content of the diets be-
tween studies consistent, and to ensure a constant n−6 PUFA level
across all studies. This allows for easier comparisons between various
studies. The fatty acid composition of the diet as measured by GC-FID
is shown in Table 1.
2.3. Surgery and 2H5-ALA and U-
13C-EPA infusion
At 8 weeks post-weaning, rats were subjected to surgery to implant
a catheter into each of the jugular vein and the carotid artery, as
previously described in detail [28]. Modiﬁed from the method of
Rapoport, Igarashi, and Gao [26]; 0.563 μmol/100 g body weight of
2H5-ALA (purity N95% conﬁrmed by GC-FID and GC–MS; Cayman
Chemical, Ann Arbor, MI) and 0.563 μmol/100 g body weight of U-13C-
EPA (purity determined to be approximately 35% 13C20, 30% 13C19, 20%
13C18 and 15% 13C16/17 by GC–MS; generously provided by Dr. Joseph
Hibbeln, National Institutes of Health, Bethesda, MD) was infused into
the jugular vein for 180 min. Due to the presence of non-uniformlylabeled 13C-EPA all calculations were performed using the 13C19 isotope
as this isotope demonstrated minimal background interference during
HPLC–MS analysis, and will henceforth continue to be referred to as
13C-EPA. Infusate preparation, 3-hour steady state infusions and blood
collections (0, 30, 60, 90, 120, 150 and 180min)were performed as pre-
viously described in detail [28]. All blood samples were centrifuged for
10 min (PC-100 microcentrifuge; Diamed, ON, Canada) and the plasma
was collected and stored at−80 °C.
2.4. Determination of plasma volume
Plasma volume was determined using the method of Schreihofer,
Hair and Stepp andmodiﬁed by our lab [24,29]. Brieﬂy, a known amount
of Evans Blue dye was injected into the jugular vein of the rats. 15 min
following injection, 1 mL of blood was drawn from the carotid artery,
twice. The plasma was collected as described above and 100 μL of
plasma was diluted into 1 mL of saline. Absorbance of plasma in saline
was determined at 604 nm with a Nanodrop 1000 and compared to a
standard curve, and the concentration of the Evans Blue dye was
determined. Concentration of the dye was then used to determine
plasma volume.
2.5. Lipid extraction
Total lipid extracts (TLE) were obtained from plasma by themethod
of Folch, Lees, and Sloane Stanley [30]. Brieﬂy, lipids from thawed plas-
ma was extracted with of 2:1:0.8 chloroform:methanol:0.88% potassi-
um chloride (by volume). For baseline total esteriﬁed fatty acid
determinations, extraction solvents contained 10.9 μg of heptadecanoic
acid (17:0, NuCheck Prep Inc., Elysian, MN, USA) and 28.3 μg of di:17:0
phosphatidylcholine (Avanti Polar Lipids Inc., Alabaster, AL, USA) as in-
ternal standards. For plasma unesteriﬁed and esteriﬁed 2H5 and 13C fatty
acid enrichment and unlabeled baseline plasma unesteriﬁed fatty acid
determinations, extraction solvents contained 272 ng of 2H8-
arachidonic acid (ARA, 20:4n-6, Cayman Chemical, Ann Arbor, MI,
USA) as an internal standard. The mixtures were vortexed, centrifuged
at 500 g for 10 min, and the lower, chloroform lipid-containing layer
was pipetted into a new test tube. For unesteriﬁed fatty acid determina-
tions, half of the stable isotope enriched plasma and all of the baseline
plasma TLE were evaporated under N2 gas, reconstituted in 100 μL of
water/acetonitrile (50:50 v/v) and stored at −80 °C until HPLC–MS
determination of the enrichment of 2H5-ALA and 13C-EPA isotopes in
the unesteriﬁed fatty acid lipid fraction of infused blood, and baseline
plasma unesteriﬁed ALA and EPA, respectively. The remaining half of
the TLE for total fatty acid 2H and 13C enrichment was stored
at−80 °C until further analysis.
2.6. Transesteriﬁcation and GC-FID
Baseline plasma TLE for determination of total unlabeled esteriﬁed
fatty acids was performed by transesteriﬁcation to fatty acid methyl
esters (FAMEs) using 2 mL 14% boron triﬂuoride in methanol with
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gas chromatograph (Bruker, Billerica, MA, USA) equipped with a DB-23
30 m × 0.25 mm i.d. × 0.25 μm ﬁlm thickness, (50%-Cyanopropyl)-
methylpolysiloxane, capillary column (J&W Scientiﬁc from Agilent
Technologies, Mississauga, ON) with helium as the carrier gas. Samples
(1 μL) were introduced by a Varian CP-8400 autosampler into the
injector heated to 250 °C in splitless injectionmode. Initial temperature
was 50 °C with a 2 min hold followed by a 20 °C min ramp to 170 °C
with a 1 min hold, a 3 °C/min ramp to 212 °C with a 9 min hold for a
total run time of 32min [31]. The ﬂame ionization detector temperature
was 300 °C with air and helium make-up gas ﬂow rates of 300
and 29 mL/min, respectively, and a sampling frequency of 20 Hz.
Peaks were identiﬁed by retention times through comparison to an
external mixed standard sample (GLC-674, Nu Chek Prep Inc., Elysian,
MN, USA).
2.7. Plasma lipid hydrolysis of isotopically enriched total fatty acid pool
The remaining half TLE (previously stored at−80 °C) from isotopi-
cally infused plasma was used to determine total fatty acid enrichment
and was evaporated under N2 gas and the lipids were hydrolyzed in
2 mL of 10% potassium hydroxide in methanol at 70 °C for 30 min, as
previously described [32]. The fatty acid extract was evaporated under
nitrogen, reconstituted in 100 μL of water/acetonitrile (50:50 v/v) and
stored at−80 °C until HPLC–MS determination of the enrichment of
2H5 and 13C isotopes in the total fatty acids.
2.8. Fatty acid determination by HPLC–MS
Enriched fatty acids were detected using a Sciex QTRAP 5500 MS
(Sciex, Framingham, MA, USA) and an Agilent 1290 LC system (Agilent
Technologies, Santa Clara, CA, USA) equipped with a Kinetex Biphenyl
column (2.1 × 50 mm, 2.6 μm; Phenomemex, Torrance, CA, USA). The
initial HPLC conditions of elution were set at 300 μL/min gradient sys-
tem consisting of 50% A (water + 0.004% propionic acid) and 50% B
(acetonitrile) ramping to 100% B at 6 min. The gradient started with
50% (A) and 50% (B) and maintained for 1.5 min, increased to 100%
(B) from 1.5 to 6 min and maintained at 100% B for 4 min to complete
the total run of 10 min. The MS was operated in negative electrospray
ionization mode with a source temperature of 600 °C and the ion
spray voltage setting of−4500 eV. Data was acquired bymultiple reac-
tionmonitoring (MRM)modewithmass transitions as follows: 277.2 to
59.0 (m/z) for ALA, 282.2 to 59.0 for 2H5-ALA, 301.2 to 257.2 for EPA,
306.2 to 262.2 for 2H5-EPA, 320.2 to 275.2 for 13C19-EPA, 334.2 to
290.0 for 2H5-DPAn-3, 348.2 to 304.2 for 13C19-DPAn-3, 332.2 to 288.2
for 2H5-DHA, 346.2 to 302.2 for 13C19-DHA and 311.2 to 213.2 for the
internal standard 2H8-ARA. Data analysis and peak integration was
performed using Analyst 1.6.2 software from Sciex. Sample
concentrations were calculated by plotting peak area ratios
(analyte/internal standard) against calibration curves generated
from extracted standard mixes. Labeled fatty acid concentrations
for a selected animal were conﬁrmed with an Agilent 5977A MS
(Agilent Technologies, Santa Clara, CA, USA) by negative chemical
ionization connected to an Agilent 7890B GC following esteriﬁcation
to pentaﬂuorobenzyl esters of extracted and hydrolyzed lipids by a
method described previously [32].
2.9. Equations
To determine the DHA synthesis rates from ALA and EPA, the ap-
pearance of 2H5-DHA and 13C19-DHA, respectively, in the plasma-
esteriﬁed pool were measured and ﬁt to a Boltzmann sigmoidal curve
([2H/13C-DHA] × plasma volume vs. time) using nonlinear regression
[24] (Graphpad Prism Version 4.0, La Jolla, CA, USA). At any point on
the curves, the slope (S) is determined by the ability of the body to syn-
thesize 2H5-DHA from 2H5-ALA or 13C19-DHA from 13C19-EPA and theability of the periphery to uptake 2H5-DHA (Eq. (1)) or 13C19-DHA
(Eq. (2)), respectively.
S ¼ k1;DHA 2H5−ALA
 
unesterified−k−1;DHA
2H5−DHA
 
esterified ð1Þ
S ¼ k1;DHA 13C19−EPA
 
unesterified−k−1;DHA
13C19−DHA
 
esterified ð2Þ
where k1,DHA is the steady-state synthesis-secretion coefﬁcient for
DHA representing a measure for the amount of infused label that is
converted to downstream products, [2H5-ALA]unesteriﬁed and [13C19-
EPA]unesteriﬁed are the plasma concentrations of the infusate, k−1,DHA is
the disappearance coefﬁcient for DHA, and [2H5/13C19-DHA] is the
concentration of DHA in the plasma that has been synthesized from
the respective infusate, packaged into lipoprotein and secreted into
the plasma. The k1,n for DHA fromALAversus EPA can then be compared
directly when the speciﬁc activities for each are equal.
Themaximum ﬁrst derivative (Smax) of the curves are assumed to be
the time point when the uptake of esteriﬁed labeled DHA from the
periphery is negligible, i.e., 0 (Eqs. (3) and (4)).
Smax ¼ k1;DHA 2H5−ALA
 
unesterified−0 ð3Þ
Smax ¼ k1;DHA 13C19−EPA
 
unesterified−0 ð4Þ
Therefore, the derivative at this point is equal to the rate of 2H5-DHA
or 13C-DHA synthesis-secretion. By correcting the Smax by the substrate
tracee:tracer ratio, the rates of actual DHA synthesis–secretion are de-
termined, Jsyn,DHA (nmol/min) [24].
Jsyn;DHA ¼ Smax ALA½ unesterified= 2H5−ALA
 
unesterified
 
¼ k1;DHA ALA½ unesterified ð5Þ
Jsyn;DHA ¼ Smax EPA½ unesterified= 13C19−EPA
 
unesterified
 
¼ k1;DHA EPA½ unesterified ð6Þ
The diet consumed for this study contained no long-chain (LC)PUFA,
therefore it can be assumed that the plasma total LCPUFAwere constant
during the infusion period. Therefore, the turnover rate (FLCPUFA) and
half-life (t1/2,LCPUFA) of total LCPUFA in the plasma can be determined
by Eqs. (7) and (8), respectively.
FLCPUFA ¼ JLCPUFA= Vplasma  LCPUFA½ esterified
  ð7Þ
t1=2;LCPUFA ¼ 0:693=FLCPUFA ð8Þ
2.10. Statistics
Differences in DHA synthesis rates from ALA and EPA precursors
were assessed by paired t-test due to the fact that 2H5-ALA and U-13C-
EPA tracers were infused simultaneously within each individual rat
(Graphpad Prism version 4.0). Normality was assessed by the Shapiro-
Wilk test for normality, and in the case of non-normally distributed
groups the data was log transformed prior to paired t-test. All data is
presented as mean ± SEM.
3. Results
3.1. Body weight and plasma volume
Following eight weeks of feeding on the 2% ALA diet, mean rodent
body weights were 434± 15 g, and are in agreement with previous re-
ports from our lab on rodents of the same age, strain and similar dietary
ALA composition. Plasma volumes were previously determined in our
laboratory at 0.018 mL/g body weight in the aforementioned Long
Fig. 1. Baseline unesteriﬁed and esteriﬁed fatty acid concentrations in Long Evans rats
following an 8-week 2% ALA diet. Values are expressed as mean ± SEM, n = 6. ALA, α-
linolenic acid; DHA, docosahexaenoic acid; DPAn-3, n−3 docosapentaenoic acid; EPA,
eicosapentaenoic acid.
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estimated to be 7.8 ± 0.3 mL.
3.2. Baseline plasma omega-3 PUFA concentrations
Blood sampleswere drawn from the carotid artery one day after sur-
gery and two days prior to stable isotope infusion for plasma
unesteriﬁed fatty acid and total fatty acid concentrations. Plasma
unesteriﬁed fatty acid concentrations were determined to be 4.8 ± 1.0
and 0.8 ± 0.3 nmol/mL for ALA and EPA, respectively (Fig. 1a). Plasma
total or esteriﬁed fatty acid concentrations were determined to be
45.8 ± 9.2, 31.3 ± 7.1 and 253 ± 24 nmol/mL for EPA, DPAn-3 and
DHA, respectively (Fig. 1b).
3.3. Plasma 2H5 and
13C PUFA concentrations during 3 h infusion
Blood samples collected throughout the stable isotope infusion from
30, 60, 90, 120, 150 and 180 min were used to determine the average
exposure levels and these values were subsequently used in
Eqs. (1)–(6). Average plasma unesteriﬁed concentrations of the infused
isotopes were 1.36 ± 0.11 and 0.28 ± 0.01 nmol/mL for 2H5-ALA and
13C-EPA, respectively (Fig. 2). Although the 2H5-ALA is signiﬁcantly
higher than 13C-EPA, the speciﬁc activities of 2H-ALA and 13C-EPA to un-
labeled ALA (0.28 ± 0.12) and EPA (0.34 ± 0.16), respectively, are not
statistically different. Although the current study design is limited by
the use of a single time point for the unlabeled unesteriﬁed fatty acid
pool, pilot work fromour lab indicates that 13C-EPA/EPA speciﬁc activity
remains sufﬁciently stable during a 3-hour infusion protocol rangingbe-
tween 0.30 and 0.35. In addition, the research group that developed
these kinetic models has shown that the speciﬁc activity does not
change over the course of a shorter 10 min infusion time [33,34].
3.4. Omega-3 PUFA synthesis-secretion coefﬁcients, rates, turnover rates
and half-life
Synthesis-secretion parameters were determined for maximal rate
of synthesis-secretion (Smax, nmol/min), synthesis-secretion coefﬁcient
(k1,n, nmol/min), synthesis-secretion rate (Jn, nmol/min), daily
synthesis-secretion rates (nmol/day), turnover (Fn, /day) and halﬂife
(t1/2,n, days) for EPA, DPAn-3 and DHA, where n is equal to each n−3
LCPUFA product (Table 2). Representative infusion curves, maximum
ﬁrst derivatives (Smax) and representative HPLC chromatograms are
also presented for the synthesis-secretion of DPAn-3 and DHA (Fig. 3).
The Smax for EPA and DHA showed no signiﬁcant differences between
ALA and EPA sources, however, the Smax for DPAn-3 derived from EPA
is 46% higher than from ALA. The k1,n, representing the synthesis-
secretion coefﬁcient for the production of each n−3 LCPUFA product
from plasma unesteriﬁed ALA and EPA is higher from EPA by 8-fold
for plasma esteriﬁed EPA, 6.5-fold for esteriﬁed DPAn-3 and 13-fold
for esteriﬁed DHA. For both precursors, the k1,n is lower the further
along in the metabolic pathway they must travel (EPA → DPAn-
3 → DHA). Interestingly, although the synthesis-secretion coefﬁcient
(k1,n) for n−3 LCPUFA production is higher from EPA vs. ALA, there
are no signiﬁcant differences in the daily synthesis secretion rates
(nmol/day) of 1587 ± 592 vs. 1628 ± 366 for EPA, 853 ± 279 vs.
1139 ± 484 for DPAn-3 or 97.6 ± 28.2 vs. 172 ± 62 for DHA from
ALA and EPA, respectively. Again, daily synthesis-secretion is lower for
each individual n−3 LCPUFA the further along in the pathway the
ALA or EPA precursormust travel. Finally, there are no signiﬁcant differ-
ences in Fn or t1/2,n for all n−3 PUFA derived from either ALA or EPA.
4. Discussion
In the current study, we demonstrate no differences in the daily
synthesis-secretion rates of DHA, DPAn-3 or EPA when comparing
plasma sources of ALA versus EPA from Long Evans rats with 2% ALAas the only source of n−3 fatty acids in their diet. Daily synthesis-
secretion rates are determined to be 1587 ± 592, 853 ± 279 and
97.6 ± 28.2 nmol/day from ALA and 1628 ± 366, 1139 ± 484 and
172± 62 from EPA for EPA, DPAn-3 and DHA, respectively. Interesting-
ly, the synthesis-secretion coefﬁcient for each of the aforementioned
n−3 metabolites, as determined by the k1,n representing labeled pre-
cursor to product conversion only (mL/min), is signiﬁcantly higher
from EPA compared to ALA and was determined to be 0.238 ± 0.071,
0.129 ± 0.027 and 0.013 ± 0.003 mL/min from ALA and 1.92 ± 0.55,
0.856 ± 0.13 and 0.168 ± 0.071 nmol/min from EPA for EPA, DPAn-3
and DHA, respectively. This k1,n value is driven entirely by the appear-
ance of the isotopically enriched PUFA product (i.e. 2H-DHA) relative
to the presence of the unesteriﬁed labeled precursor/infusate in the
plasma (i.e. 2H-ALA). The conclusions regarding the differences in k1,n
or synthesis-secretion coefﬁcient, are strengthenedwhen speciﬁc activ-
ities of each labeled substrate are equal, as is the case presently. How the
k1 value translates to actual synthesis rates is then solely determined by
the free unlabeled plasma unesteriﬁed fatty acid precursor – in this
study either free unlabeled ALA or EPA. As such, the high synthesis-
secretion coefﬁcient for the production of n−3 metabolites from EPA
compared to ALA is balanced by the high plasma unesteriﬁed ALA
(4.8 ± 1.0, nmol/mL) in comparison to plasma unesteriﬁed EPA
(0.8 ± 0.3).
A 2% ALA diet such as the one administered in the present study is
well within a normal intake range representing 0.5% of energy intake,
which is slightly lower than recommendations for nutritional adequacy
of 0.6–1.2% of energy in humans [8]. However, ALA is not normally the
only source of n−3 PUFA in the diet. North Americans' daily dietary in-
take of EPA, DPAn-3 and DHA is estimated to be 100–200 mg [9,35,36]
with EPA alone at b50 mg [7,37] versus approximately 1500 mg of
ALA [4,8–10], and would suggest that even at normal dietary levels
the contribution of unesteriﬁed ALA in the plasma would continue to
Fig. 2. Plasmaunesteriﬁed 2H5-ALA and 13C-EPA during the 3-hour steady state infusion. A,
Changes in plasma unesteriﬁed labeled fatty acid over 3 h. B, Representative HPLC–MS
chromatograms for each infused isotope from a single rat after 3 h of infusion. Values
are expressed as mean ± SEM, n = 6. ALA, α-linolenic acid, 18:3n-3; EPA,
eicosapentaenoic acid, 20:5n-3.
Table 2
Kinetic parameters for EPA, DPAn-3 and DHA whole-body synthesis-secretion as determined b
Fatty acid (n) Source Smax (nmol/min) k1,n (mL/min) Jn (nmol/min)
DHA ALA 0.019 ± 0.004 0.013 ± 0.003 0.068 ± 0.020
EPA 0.051 ± 0.024 0.168 ± 0.071a 0.120 ± 0.043
DPAn-3 ALA 0.166 ± 0.036 0.129 ± 0.027 0.592 ± 0.194
EPA 0.242 ± 0.037a 0.856 ± 0.13a 0.791 ± 0.336
EPA ALA 0.350 ± 0.134 0.238 ± 0.071 1.10 ± 0.41
EPA 0.550 ± 0.167 1.92 ± 0.55a 1.13 ± 0.254
Data are expressed as means ± SEM. Smax =maximum ﬁrst derivative, k1,n = synthesis-secret
When data was determined to be not normally distributed by asmeasured by the Shapiro-Wilk
acid, 18:3n-3; EPA, eicosapentaenoic acid, 20:5n-3; DPAn-3, omega-3 docosapentaenoic acid, 2
a Represents signiﬁcant differences between ALA and EPA sources by paired t-test (p b 0.05
1001A.H. Metherel et al. / Biochimica et Biophysica Acta 1861 (2016) 997–1004signiﬁcantly outweigh thehigher synthesis-secretion coefﬁcient forme-
tabolite production from EPA. However, it is not known if small in-
creases in dietary EPA from 0% in the present study to a normal
dietary composition of approximately 0.1% (50 mg EPA in 50–100 g
total fat intake) of fatty acids would yield an appreciable effect on the
EPA-derived daily synthesis-secretion rate of n−3 LCPUFA through
changes in plasma unesteriﬁed EPA concentrations. Unesteriﬁed EPA
concentrations have previously been determined to be 0.32 [38] and
0.22 [39] nmol/mL in humans, 2.2 nmol/mL in mice [40] and 1.0 [24]
and 1.5 nmol/mL [41] in rats, and these values are in relative agreement
with our own (0.8±0.3, nmol/mL). Fish oil supplementation in humans
providing on average 215 (0.22% of total fat intake), 430 (0.43%) and
860 mg/day (0.86%) EPA increases plasma unesteriﬁed EPA by 63, 104
and 211% [42], respectively, indicating a relatively linear increase of
plasma unesteriﬁed EPA to increases in dietary EPA. Percent of fat in-
takes are based on studies suggesting that average dietary fat intake
for males aged 18–35 years at approximately 100 g per day [3,35,37].
Using these values, we can hypothesize that increasing dietary EPA
moderately from 0 to 0.1% EPA in total fatty acids may increase daily
synthesis-secretion of DHA by up to 25%, and a diet providing as high
as 1% of fatty acids as EPA would increase DHA synthesis-secretion
from plasma EPA at least 3-fold assuming the k1,n remains stable at
these dietary EPA levels. Our lab has demonstrated previously that in-
creasing dietary linoleic acid (LNA, 18:2n-6) composition from 1.5% to
11% of total fat signiﬁcantly increases the daily arachidonic acid (ARA,
20:4n-6) synthesis-secretion rate, however, no further increases ARA
synthesis-secretion were shown at 53% LNA dietary intake levels [28].
Future steady-state infusion studies on EPA-containing diets must be
performed to conﬁrm whether increasing EPA in the diet can yield
higher daily DHA synthesis-rates.
Previous studies have assessed the plasma response of n−3 metab-
olites to increased ALA or EPA intake. Supplementation with ALA of be-
tween 1 and 15 g per day across a variety of populations reveals no
signiﬁcant increases in plasma phospholipid DHA, although plasma
phospholipid EPA increases 2–3 fold over the same supplementation
range [43]. However, in humans with low or non-existent DHA diets
such as vegetarians or vegans, ALA feeding can increase plasma DHA
[44]. Supplementation of an overweight, mildly hyperlipidemic male
population with 4 g per day EPA for 4 weeks increases serum EPA by
494%, DPAn-3 by 87% and DHA non-signiﬁcantly by 9% [45], however,
supplementation with DHA increases serum DHA by 167%. These
human intervention studies suggest that while dietary EPA may in-
crease plasma DHA more so than ALA, overall increases in DHA remain
relativelyminor, and themost successfulmethod for increasing a partic-
ular fatty acid in the body is through intake of the fatty acid of interest,
whether it is EPA, DPAn-3 or DHA. Interestingly, supplementation of
2.5% DPAn-3 in total fatty acids in rats is also ineffective at increasing
blood DHA concentrations [41]. However, a lack of an increase in DHA
in response to increases in ALA, EPA or DPAn-3 intake is not necessarily
indicative of a lack of an increase in DHA synthesis-secretion. Diet has
been shown to affect the half-life of DHA in the body [21,24], and any in-
crease in DHA synthesis-secretion from a speciﬁc fatty acid precursory co-infusion of 2H-ALA and 13C-EPA over 3 h.
Daily synthesis-secretion rate (nmol/day) Fn (/day) t1/2,n (days)
97.6 ± 28.2 0.049 ± 0.014 23.90 ± 7.57
172 ± 62 0.082 ± 0.026 18.76 ± 7.04
853 ± 279 3.41 ± 0.77 0.277 ± 0.073
1139 ± 484 3.98 ± 1.05 0.263 ± 0.076
1587 ± 592 6.65 ± 3.55 0.307 ± 0.118
1628 ± 366 4.93 ± 0.81 0.162 ± 0.027
ion coefﬁcient, Jn = synthesis rate, Fn = turnover, t1/2,n = half-life. N = 6 for both groups.
test for unequal variances, data was log transformed prior to paired t-test. ALA,α-linolenic
2:5n-3; DHA, docosahexaenoic acid, 22:6n-3.
).
Fig. 3. Representative infusion curves, ﬁrst derivatives and HPLC chromatograms for each labeled omega-3 LCPUFA (DPAn-3 or DHA)metabolite. A, Infusion curves; plasma volumes (mL)
(Vplasma) × concentration of esteriﬁed 2H5/13C-LCPUFA ([2H5/13C-LCPUFA]est) plotted against time (min) and ﬁt to a sigmoidal curve. This represents the appearance of 2H5 and 13C in a
speciﬁc LCPUFA during a 3-hour steady state infusion of 2H5-ALA and 13C-EPA in a single rat. B, First derivatives of the curves from A. The maximum ﬁrst derivative (Smax) is used to
determine the synthesis rate for each LCPUFA. C, Representative HPLC–MS chromatograms for each labeled LCPUFA from a single rat. DHA, docosahexaenoic acid, 22:6n-3; DPAn-3,
n−3 docosapentaenoic acid, 22:5n-3; EPA, eicosapentaenoic acid, 20:5n-3; LCPUFA, long chain polyunsaturated fatty acid.
1002 A.H. Metherel et al. / Biochimica et Biophysica Acta 1861 (2016) 997–1004such as ALA or EPA could bematched by a concomitant decrease in DHA
half-life (or increase in turnover). Such limitations of dietary studies for
assessing DHA synthesis can be overcome with the use of stable iso-
topes to determine conversion and turnover of fatty acid precursors
such as ALA and EPA to DHA.Prior to ours, only one previous study has assessed the isotopic
conversion of both ALA and EPA to DHA within the same subjects
[25]. In this model of DHA synthesis, the appearance of 2H5-DHA and
13C20-DHA from simultaneous oral doses of 2H5-ALA and 13C20-EPA
metabolic precursors are determined over a period of 7 days in newborn
1003A.H. Metherel et al. / Biochimica et Biophysica Acta 1861 (2016) 997–1004infants. From this study, fractional conversion rates were determined to
be 0.04 and 0.14% from oral ALA and EPA, respectively. Fractional rates
are much higher when calculating from the plasma compartment, at
28% for ALA and 45% for EPA, however, these values would appear to
be higher compared to a separate study assessing adult fractional con-
version rates [22]. Adults orally ingested 1 g of 2H5-ALA, and fractional
conversion rates to 2H5-DHA are measured at 0.01%, 0.05% and 24%
from the oral ALA, plasma ALA and plasma EPA compartments, respec-
tively [22]. Qualitative results from these studies support our data indi-
cating that the synthesis-secretion coefﬁcient for DHA is higher when
derived from EPA as compared to ALA. However, it is likely that our
daily synthesis-secretion rates from plasma unesteriﬁed precursors
are underestimates as the labeled liver fatty acyl CoA pool becomes di-
luted at each successive metabolic step as non-labeled fatty acids
enter the n−3 metabolic pathway from other bodily sources [28], and
future studies should be aimed at accurate assessment of these labeled
liver CoA dilutions.
A higher synthesis-secretion coefﬁcient for DHA from EPA is expect-
ed as EPA requires fewermetabolic/enzymatic reactions to pass through
compared to ALA that requires two additional desaturase reactions and
one additional elongase reaction. Interestingly, both precursors are
thought to utilize what is commonly considered the rate-limiting en-
zyme [46,47], involving desaturation of tetracosapentaenoic acid (TPA,
24:5n-3) to tetracosahexaenoic acid (THA, 24:6n-3) via the Δ6-
desaturase enzyme [48,49]. If this was the onlymetabolic step requiring
the rate-limiting enzyme, it would be surprising that we have shown a
nearly 13-fold higher synthesis-secretion coefﬁcient for DHA synthesis-
secretion from EPA. However, Δ6-desaturase is also required for the
desaturation of ALA to stearidonic acid (SDA, 18:4n-3) and this would
further explain our ﬁndings suggesting a higher synthesis-secretion co-
efﬁcient for DHA synthesis from EPA over ALA as EPA only requires this
Δ6-desaturase once compared to ALA requiring it twice. Alternatively,
the second rate-limiting enzyme step would suggest that the coefﬁ-
cients for synthesis-secretion of DHA would begin to converge due to
a ‘bottleneck’ effect when comparing ALA and EPA sources, however,
the higher coefﬁcient for DPAn-3 from EPA relative to ALA (6.6-fold)
nearly doubles in the higher coefﬁcient for DHA synthesis from EPA rel-
ative to ALA (13-fold). However, this is limited somewhat by the total
amount of 13C-EPA infused being similar to the endogenous unesteriﬁed
EPA levels as thismay increase the synthesis-secretion coefﬁcient by in-
creasing substrate levels for downstream n−3 LCPUFA production.
These ﬁndings suggest that the reactions involved in the conversion of
DPAn-3 to DHA, including the second Δ6-desaturation may not be
rate-limiting, leaving only the initial Δ6-desaturation of ALA to SDA as
the rate-limiting reaction during n−3 PUFA metabolism. However, in-
creasing ALA concentrations in yeast [50] and HepG2 [51] cells to levels
many fold that of TPA – as would be the case in vivo – signiﬁcantly re-
duces FADS2 selectively for TPA in the yeast cells and saturates THApro-
duction in the HepG2 cells indicating that increasing dietary ALA could
reduce DPAn-3 conversion to DHA. Alternatively, these ﬁndings also
support recent evidence from human MCF-7 cells [52] suggesting that
the FADS2 gene previously thought to catalyze the Δ6-desaturation of
TPA to THA for DHA synthesis may in fact catalyze the Δ4-
desaturation of DPAn-3 directly to DHA. Additional studies assessing
DHA synthesis-secretion rates from target n−3 PUFA precursors is re-
quired to further elucidate the DHA synthesis pathway, particularly in
the steps requiring the conversion of DPAn-3 to DHA.
In the current study, we aimed to assess the contribution of plasma
unesteriﬁed ALA and EPA towards the whole body synthesis-secretion
of downstream n−3 PUFA metabolites on an ALA only n−3 diet that
is independent of potential confounding n−3 dietary interactions.
Our results demonstrate the synthesis-secretion coefﬁcient for DHA,
DPAn-3 and EPA from plasma unesteriﬁed EPA is signiﬁcantly higher
in comparison to ALA when rodents are fed a diet containing 2% ALA
in total fatty acids as the only source of n−3 fatty acids. However,
higher endogenous plasma unesteriﬁed ALA relative to EPA negatesthe differences in synthesis-secretion coefﬁcients resulting in no signif-
icant differences in the daily synthesis-secretion of DHA, DPAn-3 or EPA
from plasma unesteriﬁed ALA compared to EPA. As such, these results
provide evidence that individuals with higher dietary EPA intake may
have a greater ability to synthesize DHA. As such, when comparing
n−3 PUFA metabolite synthesis from ALA and EPA precursors it is im-
portant that future research assess the effects of increasing dietary
EPA intake so that a truer representation of dietary patterns and
resultant daily n−3 synthesis-secretion can be determined.
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